-
<![CDATA[Imneskibart Plus Aldesleukin Yield Antitumor Activity in Melanoma and NSCLC]]>
13 Nov 2025 19:04 GMT
… 4 weeks). Patients with NSCLC will receive imneskibart plus … clinical activity in melanoma and non-small cell lung cancer. News release. BioSpace. Published … on CPI-refractory melanoma and non-small cell lung cancer (NSCLC). Presented at: Society for …
-
Non-Small Cell Lung Cancer Therapeutics Market to Reach US$ 64.92 Billion by 2033 | Datam Intelligence
12 Nov 2025 13:38 GMT
… research accelerate access to advanced NSCLC therapies.
✅ Awareness and … ✅ Pfizer Inc.: Actively advancing NSCLC therapies — for example its drug … subscription
Related Reports:
Squamous Non-Small Cell Lung Cancer Therapeutics Market
lung cancer …
-
Neoadjuvant Nivolumab in NSCLC -- Lasting Benefit Confirmed
13 Nov 2025 14:29 GMT
This transcript has been edited for clarity.
Hello. It's Mark Kris, from Memorial Sloan Kettering. I'm reporting today on a recent paper published in The New England Journal of Medicine by Patrick Forde.
In it, he reports 5-year outcome data on a …
-
The Intricate Web of MicroRNAs in Modulating EGFR-TKI Resistance in Non-Small Cell Lung Cancer: A Comprehensive Review
11 Nov 2025 07:13 GMT
… in a significant subset of non-small cell lung cancer (NSCLC) patients, particularly those … / IGF1R pathway in non-small cell lung cancer (NSCLC). Mol Cancer. 2024;23 … EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating …
-
<![CDATA[Dr Liu on the Efficacy of Zidesamtinib in ROS1 Fusion+ NSCLC]]>
13 Nov 2025 03:20 GMT
… non–small cell lung cancer (NSCLC).
The initial analysis included patients … patients with ROS1 fusion–positive NSCLC, Liu reported. In this first … option for ROS1 fusion–positive NSCLC, Liu concluded.
-
<![CDATA[FDA Grants Fast Track Designation to AVZO-1418/DB-1418 for EGFR+, TKI-Pretreated NSCLC]]>
12 Nov 2025 17:19 GMT
… non–small cell lung cancer (NSCLC) harboring an EGFR exon 19 … with parental bivalent ADCs in NSCLC and renal cell carcinoma models … with EGFR-mutated TKI-pretreated NSCLC. News release. DualityBio. November 10 …
-
<![CDATA[Investigational Therapies and Ongoing Trials in ROS1+ NSCLC]]>
12 Nov 2025 17:21 GMT
Panelists explore the growing pipeline of investigational therapies that address limitations of currently approved ROS1 inhibitors. These include agents designed to overcome common resistance mutations and to provide improved brain penetration. Early …
-
How Targeted Therapy Is Changing Cancer Treatment
14 Nov 2025 00:19 GMT
… -targeting therapeutic for people with non-small cell lung cancer. That was followed quickly by … have proved effective in treating non-small cell lung cancer. HER2 inhibitors are used against …
-
<![CDATA[Optimizing Preclinical Data for Seamless Translation in Clinical Scenarios]]>
14 Nov 2025 00:41 GMT
… adults with previously treated advanced non-small cell lung cancer (NSCLC) with high c-Met protein …
-
<![CDATA[STK-012 Plus Pembrolizumab, Chemo Demonstrate Safety and Efficacy in NSCLC ]]>
11 Nov 2025 23:21 GMT
… PD-L1 negative nonsquamous NSCLC–a population marked … PD-L1 negative nonsquamous NSCLC and tumors with … recruiting patients with nonsquamous NSCLC who have stage 3b … PD-L1 negative nonsquamous non-small cell lung cancer. News release. Published November …
About
© 1995-2025